SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy
Journal of Cutaneous Medicine and Surgery · 2025
DOI: 10.1177/12034754251338809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Medicine and Surgery, 2025. Verfasst von Peter Y Ch'en und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, NY, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Seroconversion, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives: Tumour necrosis factor-α (TNF-α) inhibitors such as adalimumab and infliximab are commonly used in moderate-to-severe hidradenitis suppurativa (HS). While the impact of TNF-α inhibitors on outcomes after an active infection in patients with HS has been explored, their effect on the SARS-CoV-2 vaccine response remains unknown. We investigated the impact of TNF-α inhibitor therapy on the immunogenic response to the SARS-CoV-2 vaccine in patients with HS.
Methods
This is a single-centre retrospective chart review of 120 patients with recorded levels of anti-SARS-CoV-2 spike antibody. This cohort was characterized descriptively by demographics, antibody levels, vaccine brand, number of doses, and days elapsed from vaccination. These variables were then compared by usage of anti-TNF therapy. Secondary analyses included comparison by biologic type, time on biologic, and biologic dosage.
Results
We found no significant difference in seroconversion following SARS-CoV-2 vaccination while on anti-TNF therapy in HS patients; a finding that holds in comparisons between anti-TNF therapy type, time exposed to biologic, and anti-TNF dosage.
Conclusions
Patients with HS on anti-TNF therapy receiving the SARS-CoV-2 mRNA vaccine seroconvert similarly as those without anti-TNF therapy, indicating this population should receive the vaccine and expect a similar degree of protection against COVID-19 compared to HS patients who do not receive anti-TNF therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, NY, USA.
- Department of Dermatology, Keck School of Medicine of USC, Los Angeles, CA, USA.
- New York Medical College, Valhalla, NY, USA.
- Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.
ORCID-Profile: Peter Y Ch'en, Zahidul Islam, Steven R Cohen
Zitieren
APA
Ch'en, P. Y., Nosrati, A., Torpey, M. E., Toker, M., Islam, Z., Campton, K. L., & Cohen, S. R. (2025). SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754251338809
Vancouver
Ch'en PY, Nosrati A, Torpey ME, Toker M, Islam Z, Campton KL, et al. SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy. Journal of Cutaneous Medicine and Surgery. 2025. doi:10.1177/12034754251338809
BibTeX
@article{Chen2025,
author = {Ch'en, Peter Y and Nosrati, Avigdor and Torpey, McCall E and Toker, Michelle and Islam, Zahidul and Campton, Kristina L and Cohen, Steven R},
title = {SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2025},
doi = {10.1177/12034754251338809}
}
EUVIMED